Lantheus Holdings Reports Q2 2025 Results and Strategic Moves

Lantheus Holdings Inc ( (LNTH) ) has released its Q2 earnings. Here is a breakdown of the information Lantheus Holdings Inc presented to its investors.

Lantheus Holdings Inc., a leader in the radiopharmaceutical sector, focuses on developing innovative diagnostic and therapeutic products to enhance patient outcomes. In its second quarter of 2025, Lantheus reported worldwide revenue of $378 million, with a GAAP earnings per share of $1.12 and an adjusted earnings per share of $1.57. The company also announced the FDA’s acceptance of a new drug application for a PSMA PET imaging agent and completed the acquisition of Life Molecular Imaging, enhancing its portfolio with the Alzheimer’s diagnostic agent Neuraceq.

Key financial metrics for the quarter included a 4.1% decline in worldwide revenue compared to the previous year, while GAAP net income increased by 26.9%. Despite a decrease in sales of its PYLARIFY product by 8.3%, sales of DEFINITY rose by 7.5%. The company also reported a free cash flow of $79.1 million and authorized a $400 million stock repurchase program, reflecting confidence in its long-term strategy.

Strategically, Lantheus has been active with acquisitions, including Evergreen Theragnostics and Life Molecular Imaging, to diversify its revenue streams and expand its radiopharmaceutical capabilities. The company is also divesting its SPECT business to focus on PET radiodiagnostics and microbubbles. These moves are aimed at strengthening its position in the competitive radiopharmaceutical market.

Looking ahead, Lantheus has updated its corporate guidance for 2025, adjusting revenue and earnings expectations to incorporate recent acquisitions and current business conditions. The company remains focused on advancing its pipeline and expanding its commercial portfolio, positioning itself for sustained growth in the radiopharmaceutical industry.